Table 2.
Protein Tyrosine Kinases (PTKs) Targeted Drugs
| Drug/Type | PTKs | Indication |
|---|---|---|
| Cetuximab (Erbitux)/ mAb | erbB1 (EGFR) | colorectal cancer, phase III for head/neck, pancreatic cancers and NSCLC, Phase II for HCC |
| Matuzumab (EMD 72000)/ mAb | erbB1 (EGFR) | phase I/II for NSCLC, ovarian, pancreatic cancer |
| Panitumumab (ABX-EGF, Vectibix )/ mAb | erbB1 (EGFR) | colorectal cancer, phase I for refractory solid Tumors |
| Erlotinib (Tarceva)TK inhibitor | erbB1 (EGFR) | NSCLC, pancreatic cancer, phase II for HCC |
| Gefitinib (Iressa)/ TK inhibitor | erbB1 (EGFR) | NSCLC, phase I for HCC |
| EKB-569/ TK inhibitor | erbB1 (EGFR) | phase II for advanced colorectal cancer and NSCLC |
| Lapatinib (Tykerb)/ TK inhibitor | erbB1 (EGFR)/ erbB2 | advanced metastatic breast cancer |
| Canertinib (CI-1033)/TK inhibitor | Pan-erbB | phase II for SCC, ovarian and metastatic breast cancer cancer |
| Trastuzumab (Herceptin)/ mAb | erbB2 | Breast cancer |
| Imatinib (Gleevec)/TK inhibitor | ABL, PGRFR, KIT | CML, CMML, CEL, GIST |
| Bevacizumab (Avastin)*/ mAb | VEGF A | NSCLC, colorectal cancer |
| Semaxanib (SU5416)/ TK inhibitor | VEGFR, EGFR, KIT | phase II for metastatic melanoma |
| Sunitinib (Sutent)/ TK inhibitor | VEGFR, KIT, PDGFR, Flt3 | GIST, Renal cell carcinoma |
| Vatalanib/ TK inhibitor | VEGFR, PDGFR | phase III for colorectal and phase II for GIST, prostate and kidney cancer |
NSCLC, non small cell lung cancer; HCC, hepatocellular cancer; CML, Chronic myeloid leukemia; CMML, Chronic myelomonocytic leukemia; CEL, Chroniceosinophilic leukemia; GIST, Gastrointestinal stromal tumor; SCC, Squamous cell carcinoma.